from my site

Aug 25:

* Special Alert – (INCC)

With the Olympics coming to an end, all eyes will be on China, and that’s why I want everyone to turn their attention to INCC.

INCC specializes in acquiring international businesses, located in rapidly expanding Asian markets focused on three dynamic areas: healthcare, technology and the environment.

As more and more investors are looking to China for investment opportunities, INCC is providing the bridge to connect the two.

Utilizing a unique acquisition model , INCC, Inc. provides foreign companies an opportunity to gain access to U.S. capital markets. In exchange, International Consolidated Companies, Inc. retains a significant percentage of each target company, creating a diversified, growth oriented investment base that should enjoy a steady, long-term increase.

INCC is rapidly expanding their assets, with their latest press release on Friday, INCC announced that it has executed a letter of Intent to acquire the assets of Source Bio Plastics, Inc.

Source Bio Plastics ("Source") and International Consolidated Companies, Inc. (INCC) have identified the biodegradable plastic products market as a rapidly expanding segment of the overall plastics industry.

This is one of the reason I like INCC, they are able to identify what’s hot and execute their business plan in a quick manner.

INCC recently announced the acquisition of China Gene, Ltd. (Hong Kong) - which has two subsidiaries: Shanghai Huaxin High Biotechnology, Inc. and Sichuan Kelun Bio-Tech Pharmaceutical Company.

________________________

August 28:

* UPDATE on (INCC) ~

My alert on MEDT has gone up 56% over the last month, now I want everyone to turn their attention to INCC.

INCC recently announced record sales for one of their majority owned subsidiary, China Gene Ltd.

IMPORTANT: You may need to call your broker to place the trade on INCC

For 2008, its unaudited year-end revenue was $6,006,241, up 77% over 2007 year and up 250% over 2006.

"We are proving what everyone who watched the 2008 Summer Olympics Games is coming to understand: 'China works!'" said Mr. Uccello, President and CEO of International Consolidated Companies, Inc.

I'm really excited about INCC future outlook, they are expanding fast and revenues are growing!!

INCC recently announced the acquisition of China Gene, Ltd. (Hong Kong) - which has two subsidiaries: Shanghai Huaxin High Biotechnology, Inc. and Sichuan Kelun Bio-Tech Pharmaceutical Company.

Shanghai Huaxin High Biotechnology, Inc. has patents on a proprietary delivery system for the drug Interferon - used to fight Hepatitis B and C (the two single largest killers in China) and Cervical Cancer.

Studies estimate that among foreign-born Asians, one out of ten has has chronic hepatitis B infection.

According to the World Health Organization, about 60 to 80 percent of liver cancer worldwide is caused by chronic hepatitis B infection!

INCC realizes how serious Hepatitis B is considering that it is 100 times more infectious than Aids!

INCC could be a giant with their Hepatitis drug! Imagine how many lives might be saved!

According to Hong Kong Pharmaceutical Holdings Limited, Shanghai Huaxin is considered to be the first biotechnology enterprise and the birthplace of the first bioengineered medicine in China.

"The Chinese biotechnology industry is like a baby dragon, which will grow quickly and soon become hard to ignore. It’s no longer the case that the industrialized world has hegemony over biotechnology innovation," says co-author Peter A. Singer, MD, of the McLaughlin-Rotman Centre for Global Health.

Call your broker now, once analyst find out about INCC and start their coverage on it. We may see INCC trading at where it was earlier this year, which was at $1.00
o
+ We will return back on track with the reg "system" plays after this holiday weekend!